Medical Device News Magazine

SERF VT Study Presented as Part of HRS 2020 Science Late-Breaking Clinical Trial Sessions

Results Suggest Highly Effective Method to Treat Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Durablate catheter to treat VT, a leading cause of sudden cardiac death worldwide.

Thermedical® announced results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate® catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today.

Called the Saline Enhanced Radiofrequency (SERF) VT Ablation EFS, preliminary results were presented by the study’s Lead Investigator, Douglas L. Packer, M.D., professor of medicine at the Mayo Clinic, on Heart Rhythm 365, the society’s digital education platform.

“Our data from the First-in-Human EFS suggest a highly feasible approach to treating patients with recurrent VT that is resistant to other treatments,” said Dr. Packer.

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Durablate catheter to treat VT, a leading cause of sudden cardiac death worldwide. The target study population consists of patients who have failed all current forms of treatment including Implantable Cardioverter Defibrillators (ICDs), medical therapy and other forms of ablation therapy. The Durablate catheter uses a needle electrode to deliver heated, degassed saline and radiofrequency energy into the tissue to more effectively treat the tissue causing the VT than a standard, conventional ablation catheter.

Early feasibility results of 32 patients treated at six centers in the U.S. and Canada indicate that the SERF Durablate catheter is highly effective at eliminating clinical VT in patients with an acute procedural success rate of 100 percent and shows acceptable initial safety.

Five-month follow-up data demonstrate that more than half of the patients had no recurrent VT and more than 60 percent of the patients had their VT reduced by 90 percent or more. In contrast, for the six months prior to ablation, patients had a median of 40 ICD treatments (shock or antitachycardia pacing), which can significantly reduce quality of life. The Durablate catheter was used to deliver an average of 10 lesions per case and the average total procedure time was four hours and 42 minutes, which is significantly shorter than typical conventional RF procedures for patients of this nature.

“We are extremely encouraged by these early results as it puts us one step closer to advancing treatment that can reduce or eliminate VT episodes in patients,” said Michael Curley, Ph.D., FHRS, co-founder and chief executive officer of Thermedical. “Moreover, a successful and effective method to treat VT that is drastically shorter and more effective than current ablation procedures would improve quality of life considerably for people who develop, or who are at high risk of developing VT every year.

“We believe our SERF ablation therapy may serve as an adjunct to, or as a possible alternative to ICDs, and equally as important, it may be a low-cost alternative for treating VT, saving the U.S. healthcare system substantially in costs associated with current VT treatment,” added Dr. Curley.

The SERF VT EFS is underway in the U.S. at Mayo Clinic, Loyola University Medical Center, and Vanderbilt University Medical Center, and in Canada at Southlake Regional Health Centre, Montreal Heart Institute and Quebec Heart and Lung Institute.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.